PUBLISHER: DelveInsight | PRODUCT CODE: 1226646
PUBLISHER: DelveInsight | PRODUCT CODE: 1226646
"Lomitapide Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about lomitapide for Severe Hypertriglyceridemia (SHTG) in the six major markets. A detailed picture of the lomitapide for severe hypertriglyceridemia in the 6MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the lomitapide for severe hypertriglyceridemia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the lomitapide market forecast analysis for severe hypertriglyceridemia in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in severe hypertriglyceridemia.
Lomitapide is a small molecule administered orally, which is a selective inhibitor of microsomal triglyceride transfer protein (MTP), a protein necessary for the proper assembly and secretion of cholesterol containing molecules in the liver and the intestines, is currently in Phase II of its clinical development in the pipeline of Amryt Pharma for the indication Familial Chylomicronemia Syndrome. Inhibition of MTP reduces the levels of cholesterol containing molecules including cholesterol, LDL-C and triglycerides in the blood.
In December 2012, the US FDA granted authorisation for lomitapide under the trade name 'JUXTAPID' as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-highdensity lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Lomitapide Analytical Perspective by DelveInsight
This report provides a detailed market assessment of lomitapide for severe hypertriglyceridemia in the six major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of lomitapide for severe hypertriglyceridemia covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions